Navigation Links
Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
Date:11/24/2008

SOUTH SAN FRANCISCO, Calif., Nov. 24 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced an agreement with Baxter Oncology GmbH for the commercial manufacture and supply of injectable picoplatin drug product. Poniard is developing picoplatin, its lead product candidate, as a potential new platform product for the treatment of solid tumors. The Company is evaluating picoplatin in four clinical trials, including an ongoing pivotal Phase 3 trial in small cell lung cancer, Phase 2 trials in colorectal and prostate cancers, and a Phase 1 trial of an oral formulation.

"This agreement with Baxter Oncology GmbH for the commercial supply of picoplatin represents the achievement of another important milestone in our plan to develop picoplatin as an oncology platform compound addressing multiple indications, combinations and formulations," said Ronald Martell, president and chief operating officer of Poniard. "Baxter Oncology GmbH's industry-leading technology and state-of-the art finish/fill production capabilities will help ensure we meet our production and quality goals as we move toward commercialization of picoplatin in 2010."

In March 2008, Poniard entered into an agreement with W. C. Heraeus GmbH to manufacture picoplatin active pharmaceutical ingredient (API) and be ready to ship commercial quantities of picoplatin by 2009. Heraeus is the current manufacturer of picoplatin API for the Company's four ongoing clinical trials.

About Picoplatin

Picoplatin has an improved safety profile relative to existing platinum-based cancer therapies and is designed to overcome platinum resistance associated with chemotherapy in solid tumors. It is being studied in multiple cancer indications, combinations and formulations. Pic
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 Biscayne Pharmaceuticals, Inc ., today ... growth hormone-releasing hormone (GHRH) technology will be discussed in a ... Meeting. The data show that the family of receptors ... is present on many primary breast cancer cells regardless ... antagonists could have broad anti-cancer potential in breast cancer. ...
(Date:5/28/2015)... May 28, 2015 CD-adapco, the ... Engineering software, announced today it is joining the ... will provide state-of-the-art engineering simulation tools for analyzing ... expertise and experiences in analyzing particle flow that ... and advance the understanding of flow modeling solutions. ...
(Date:5/28/2015)... Glenn Keet, CEO of Clinovo , ... Clinical Data Integration with EDC Systems ” at the ... on June 14th-18th. , During the presentation, Glenn Keet ... EDC, and will examine the value of patient engagement, ... health records/electronic medical records integration. , The presentation ...
(Date:5/28/2015)... May 28, 2015 Global futurist ... point to ask his audiences if they are ... including robotics, solar cells, fuel cells, rapid health ... advanced battery storage technology, driverless cars, artificial intelligence ... but inexpensive online education. , While the ...
Breaking Biology Technology:Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2Futurist Jack Uldrich to Deliver 4 Keynote Addresses in June 2
... May 20 Dendreon Corporation (Nasdaq: DNDN ) today announced ... (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to ... (ASCO) in Chicago on Monday, June 7 at ... , "With ...
... Former ... campuses -- San Francisco and Berkeley -- to jointly launch the first program of its ... , ... Former Intel Corp. chief executive Andy Grove has pledged $1.5 million to two University of ...
... Synthetic Genomics Inc. (SGI), a privately held company ... and the environment, applauds the creation of the first synthetic bacterial cell by ... $30 million in funding for this work since 2005. , ... SGI was founded in 2005 by Drs. ...
Cached Biology Technology:Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting 2Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting 3Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting 4Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting 5Grove Gift Launches Translational Medicine Program at UCSF & UC Berkeley 2Grove Gift Launches Translational Medicine Program at UCSF & UC Berkeley 3Grove Gift Launches Translational Medicine Program at UCSF & UC Berkeley 4Synthetic Genomics Inc. Applauds the Venter Institute's Work in Creating the First Synthetic Bacterial Cell 2Synthetic Genomics Inc. Applauds the Venter Institute's Work in Creating the First Synthetic Bacterial Cell 3
(Date:5/26/2015)... 2015 Research and Markets ... the "Saudi Arabia Biometric Systems Market Forecast ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems market ... projected to grow at over 22% CAGR through ... to the surging demand for better biometric technologies ...
(Date:5/21/2015)... , May 21, 2015 The Sync ... of music for health, today announced a collaborative partnership ... The partnership will center on collaboration on original research, ... first step in the collaboration, The Sync Project and ... "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... DUBLIN , May 19, 2015 /PRNewswire/ ... ) has announced the addition of the  ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A ... provides an in-depth analysis of the current ... introduction of gene-based tests, their working principles ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2
... As the nation becomes more aware of health ... struggling to find ways to make healthy living easier. ... ideas into sustainable changes through the Healthy Lifestyle Initiative. ... counties, is aimed at changing environments to increase the ...
... at the University of California, Riverside have found that ... heritable trait that can be passed down genetically to ... they found that activity level can be enhanced with ... animals for particular genetic traits. Their experiments showed ...
... is turning out to be more complicated than many ... by the University of Leicester is set to investigate ... is to receive a 1.37 million Research Programme Award ... carry out a major study on The Impact of ...
Cached Biology News:Resource-savvy communities generate healthy, sustainable changes 2Capacity for exercise can be inherited, UC Riverside biologists find 2Capacity for exercise can be inherited, UC Riverside biologists find 3Roots of the British come under new scrutiny 2Roots of the British come under new scrutiny 3Roots of the British come under new scrutiny 4
... Cloning Kit, 40 reactions. Optimized for ... all PCR products with blunt or ... by offering consistently better signal-to-noise ratios ... positive clones.Amplicons generated by proof-reading thermostable ...
PCR System for increased fidelity, yield and length of PCR products. Amplifies targets up to 10 kb from human genomic DNA....
... Two separate vials containing 200 ... same sequence used as antigens for ... 160890) To be ... cyclase polyclonal antiserum (Catalog No. 160890) ...
...
Biology Products: